연구동향 분석

다시 보는 알츠하이머병의 아밀로이드 가설

김병수(Byung Soo Kim) 2014년

논문상세정보
인용/피인용
' 다시 보는 알츠하이머병의 아밀로이드 가설' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • 내과학
  • alzheimer disease
  • amyloid beta
  • amyloid plaque
  • amyloidbeta-proteinprecursor
  • amyloidprecursorproteinsecretases
  • 아밀로이드
  • 아밀로이드-베타
  • 아밀로이드판
  • 알츠하이머 병
  • 전구물질단백질
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
1,498 0

0.0%

' 다시 보는 알츠하이머병의 아밀로이드 가설' 의 참고문헌

  • gamma-Secretase inhibitors and modulators for Alzheimer’s disease
    Wolfe MS J Neurochem 120 (Suppl 1) : 89 ~ 98 [2012]
  • beta-amyloid fibrils induce tau phosphorylation and loss of microtubule binding
    Busciglio J Neuron 14 : 879 ~ 888 [1995]
  • beta-Amyloid burden in healthy aging : regional distribution and cognitive consequences
    Rodrigue KM Neurology 78 : 387 ~ 395 [2012]
  • alpha-secretase in Alzheimer’s disease: molecular identity, regulation and therapeutic potential
    Lichtenthaler SF J Neurochem 116 : 10 ~ 21 [2011]
  • Visualization of A beta 42(43)and A beta 40 in senile plaques with end-specific A beta monoclonals : evidence that an initially deposited species is A beta 42(43)
    Iwatsubo T Neuron 13 : 45 ~ 53 [1994]
  • Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease
    Salloway S New England Journal of Medicine 370 : 322 ~ 333 [2014]
  • Transport pathways for clearance of human Alzheimer’s amyloid beta-peptide and apolipoproteins E and J in the mouse central nervous system
    Bell RD J Cereb Blood Flow Metab 27 : 909 ~ 918 [2007]
  • Transgenic mice overexpressing amyloid beta protein are an incomplete model of Alzheimer disease
    Schwab C Exp Neurol 188 : 52 ~ 64 [2004]
  • Tramiprosate in mild-to-moderate Alzheimer’s disease - a randomized, double-blind, placebo-controlled, multi-centre study(the Alphase Study)
    Aisen PS Arch Med Sci 7 : 102 ~ 111 [2011]
  • Therapeutic potential of gamma-secretase inhibitors and modulators
    Imbimbo BP Curr Top Med Chem 8 : 54 ~ 61 [2008]
  • Therapeutic effects of PKC activators in Alzheimer’s disease transgenic mice
    Etcheberrigaray R Proc Natl Acad Sci USA 101 : 11141 ~ 11146 [2004]
  • The spatial patterns of plaques and tangles in Alzheimer’s disease do not support the ‘cascade hypothesis’
    Armstrong RA Dementia 4 : 16 ~ 20 [1993]
  • The role of beta amyloid in Alzheimer’s disease: still a cause of everything or the only one who got caught?
    Verdile G Pharmacol Res 50 : 397 ~ 409 [2004]
  • The possible role of complement activation in Alzheimer disease
    McGeer PL Trends Mol Med 8 : 519 ~ 523 [2002]
  • The natural history of Alzheimer disease : a longitudinal presymptomatic and symptomatic study of a familial cohort
    Godbolt AK Arch Neurol 61 : 1743 ~ 1748 [2004]
  • The mechanism of gamma-Secretase dysfunction in familial Alzheimer disease
    Chavez-Gutierrez L EMBO J 31 : 2261 ~ 2274 [2012]
  • The clinical phenotype of familial and sporadic late onset Alzheimer’s disease
    Holmes C Int J Geriatr Psychiatry 17 : 146 ~ 149 [2002]
  • The amyloid hypothesis of Alzheimer's disease:progress and problems on the road to therapeutics
    Hardy J Science 297 : 353 ~ 356 [2002]
  • The amyloid cascade hypothesis for Alzheimer’s disease : an appraisal for the development of therapeutics
    Karran E Nat Rev Drug Discov 10 : 698 ~ 712 [2011]
  • Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry
    Braak H Acta Neuropathol 112 : 389 ~ 404 [2006]
  • Serum total cholesterol, apolipoprotein E epsilon 4 allele, and Alzheimer's disease
    Notkola IL Neuroepidemiology 17 : 14 ~ 20 [1998]
  • Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer’s disease
    Goate A Nature 349 : 704 ~ 706 [1991]
  • Safety, tolerability, and antibody response of active Abeta immunotherapy with CAD106 in patients with Alzheimer’s disease: randomised, double-blind, placebo-controlled, first-in-human study
    Winblad B Lancet Neurol 11 : 597 ~ 604 [2012]
  • Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer’s disease: a phase IIa, double-blind, randomised, placebo-controlled trial
    Lannfelt L Lancet Neurol 7 : 779 ~ 786 [2008]
  • Safety and biomarker effects of solanezumab in patients with Alzheimer’s disease
    Farlow M Alzheimers Dement 8 : 261 ~ 271 [2012]
  • Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease:results from a randomized, double-blind, placebo-controlled phase III study
    Gold M Dement Geriatr Cogn Disord 30 : 131 ~ 146 [2010]
  • Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer’s disease mouse model
    Roberson ED Science 316 : 750 ~ 754 [2007]
  • Reducing amyloid plaque burden via ex vivo gene delivery of an Abeta-degrading protease: a novel therapeutic approach to Alzheimer disease
    Hemming ML PLoS Med 4 : e262 ~ [2007]
  • Reconstitution of gamma-secretase activity
    Edbauer D Nat Cell Biol 5 : 486 ~ 488 [2003]
  • Quantitative analysis of the time course of Abeta oligomerization and subsequent growth steps using tetramethylrhodamine-labeled Abeta
    Garai K Proc Natl Acad Sci U S A 110 : 3321 ~ 3326 [2013]
  • Proteolytic degradation of amyloid beta-protein
    Saido T Cold Spring Harb Perspect Med 2 : a006379 ~ [2012]
  • Primary or secondary prevention for AD: who cares?
    Frisoni GB Lancet Neurol 11 (7) : 567 ~ [2012]
  • Presynaptic localization of neprilysin contributes to efficient clearance of amyloid-beta peptide in mouse brain
    Iwata N J Neurosci 24 : 991 ~ 998 [2004]
  • Plaques and tangles and the pathogenesis of Alzheimer’s disease
    Armstrong RA Folia Neuropathol 44 : 1 ~ 11 [2006]
  • Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease
    Doody RS New England Journal of Medicine 370 : 311 ~ 321 [2014]
  • Pharmacodynamics and pharmacokinetics of the gamma-secretase inhibitor PF-3084014
    Lanz TA J Pharmacol Exp Ther 334 : 269 ~ 277 [2010]
  • Phagocytosis of amyloid-beta and inflammation : two faces of innate immunity in Alzheimer’s disease
    Fiala M J Alzheimers Dis 11 : 457 ~ 463 [2007]
  • Perspectives on future Alzheimer therapies : amyloid-beta protofibrils-a new target for immunotherapy with BAN2401 in Alzheimer’s disease
    Lannfelt L Alzheimers Res Ther 6 : 16 ~ [2014]
  • Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease
    Bard F Nat Med 6 : 916 ~ 919 [2000]
  • PPARgamma agonists as therapeutics for the treatment of Alzheimer’s disease
    Landreth G Neurotherapeutics 5 : 481 ~ 489 [2008]
  • PBT2 rapidly improves cognition in Alzheimer’s Disease : additional phase II analyses
    Faux NG J Alzheimers Dis 20 : 509 ~ 516 [2010]
  • Notch and Presenilin : regulated intramembrane proteolysis links development and degeneration
    Selkoe D Annu Rev Neurosci 26 : 565 ~ 597 [2003]
  • Neutralization of soluble, synaptotoxic amyloid beta species by antibodies is epitope specific
    Zago W J Neurosci 32 : 2696 ~ 2702 [2012]
  • Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide : a case report
    Nicoll JA Nat Med 9 : 448 ~ 452 [2003]
  • Neuropathological stageing of Alzheimer-related changes
    Braak H Acta Neuropathol 82 : 239 ~ 259 [1991]
  • Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer’s disease
    Gomez-Isla T Ann Neurol 41 : 17 ~ 24 [1997]
  • Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function
    Cleary JP Nat Neurosci 8 : 79 ~ 84 [2005]
  • Modulation of amyloid precursor protein cleavage by cellular sphingolipids
    Sawamura N J Biol Chem 279 : 11984 ~ 11991 [2004]
  • Microglial activation and amyloid deposition in mild cognitive impairment : a PET study
    Okello A Neurology 72 : 56 ~ 62 [2009]
  • Membrane-anchored aspartyl protease with Alzheimer’s disease beta-secretase activity
    Yan R Nature 402 : 533 ~ 537 [1999]
  • Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab
    Ostrowitzki S Arch Neurol 69 : 198 ~ 207 [2012]
  • Low-density lipoprotein receptor-related protein promotes amyloid precursor protein trafficking to lipid rafts in the endocytic pathway
    Yoon IS FASEB J 21 : 2742 ~ 2752 [2007]
  • Low-density lipoprotein receptor-related protein 1 : a physiological Abeta homeostatic mechanism with multiple therapeutic opportunities
    Sagare AP Pharmacol Ther 136 : 94 ~ 105 [2012]
  • Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the alpha-secretase ADAM 10
    Kojro E Proc Natl Acad Sci USA 98 : 5815 ~ 5820 [2001]
  • Loss of neprilysin function promotes amyloid plaque formation and causes cerebral amyloid angiopathy
    Farris W Am J Pathol 171 : 241 ~ 251 [2007]
  • Looking for the link between plaques and tangles
    Duyckaerts C Neurobiol Aging 25 : 735 ~ 739 [2004]
  • Long-term effects of Abeta42 immunisation in Alzheimer’s disease: follow-up of a randomised, placebo-controlled phase I trial
    Holmes C Lancet 372 : 216 ~ 223 [2008]
  • Lipidation of apolipoprotein E influences its isoform-specific interaction with Alzheimer’s amyloid beta peptides
    Tokuda T Biochem J 2 : 359 ~ 365 [2000]
  • Knockdown of ACAT-1 reduces amyloidogenic processing of APP
    Huttunen HJ FEBS Lett 581 : 1688 ~ 1692 [2007]
  • Interaction of Alzheimer’s disease amyloid beta peptide fragment 25-35 with tau protein, and with a tau peptide containing the microtubule binding domain
    Perez M J Alzheimers Dis 6 : 461 ~ 467 [2004]
  • Insights into Alzheimer disease pathogenesis from studies in transgenic animal models
    Schaeffer EL Clinics 66 (Suppl 1) : 45 ~ 54 [2011]
  • Inhibition of acyl-coenzyme A : cholesterol acyl transferase modulates amyloid precursor protein trafficking in the early secretory pathway
    Huttunen HJ FASEB J 23 : 3819 ~ 3828 [2009]
  • Imaging beta-amyloid burden in aging and dementia
    Rowe CC Neurology 68 : 1718 ~ 1725 [2007]
  • Gantenerumab : a novel human anti-Abeta antibody demonstrates sustained cerebral amyloid-beta binding and elicits cell-mediated removal of human amyloid-beta
    Bohrmann B J Alzheimers Dis 28 : 49 ~ 69 [2012]
  • Exebryl-1: A novel small molecule currently in human clinical trials as a disease-modifying drug for the treatment of Alzheimer’s disease
    Snow AD Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association 5 : 418 ~ [2009]
  • Etazolate, a neuroprotective drug linking GABA(A) receptor pharmacology to amyloid precursor protein processing
    Marcade M J Neurochem 106 : 392 ~ 404 [2008]
  • Epitope and isotype specificities of antibodies to beta-amyloid peptide for protection against Alzheimer’s disease-like neuropathology
    Bard F Proc Natl Acad Sci USA 100 : 2023 ~ 2028 [2003]
  • Enhanced proteolysis of beta-amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death
    Leissring MA Neuron 40 : 1087 ~ 1093 [2003]
  • Emerging and potential therapies for Alzheimer’s disease
    Griffiths HH Expert Opin Ther Targets 12 : 693 ~ 704 [2008]
  • Efficacy and safety studies of gantenerumab in patients with Alzheimer's disease
    Panza F Expert Rev Neurother : 1 ~ 14 [2014]
  • Effects of Abeta immunization(AN1792)on MRI measures of cerebral volume in Alzheimer disease
    Fox NC Neurology 64 : 1563 ~ 1572 [2005]
  • Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease : a randomized controlled trial
    Green RC JAMA 302 : 2557 ~ 2564 [2009]
  • EHT0202 in Alzheimer's disease: a 3-month, randomized, placebo-controlled, double-blind study
    Vellas B Curr Alzheimer Res 8 : 203 ~ 212 [2011]
  • Direct and potent regulation of gamma-secretase by its lipid microenvironment
    Osenkowski P J Biol Chem 283 : 22529 ~ 22540 [2008]
  • Development of AFFITOPE vaccines for Alzheimer’s disease(AD)--from concept to clinical testing
    Schneeberger A J Nutr Health Aging 13 : 264 ~ 267 [2009]
  • Deficiency in neuronal TGF-beta signaling promotes neurodegeneration and Alzheimer’s pathology
    Tesseur I J Clin Invest 116 : 3060 ~ 3069 [2006]
  • Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors
    Wolozin B Arch Neurol 57 : 1439 ~ 1443 [2000]
  • Decreased clearance of CNS beta-amyloid in Alzheimer’s disease
    Mawuenyega KG Science 330 : 1774 ~ [2010]
  • Cyclohexanehexol inhibitors of Abeta aggregation prevent and reverse Alzheimer phenotype in a mouse model
    McLaurin J Nat Med 12 : 801 ~ 808 [2006]
  • Conversion of amyloid positive and negative MCI to AD over 3 years : an 11C-PIB PET study
    Okello A Neurology 73 : 754 ~ 760 [2009]
  • Connecting TNF-alpha signaling pathways to iNOS expression in a mouse model of Alzheimer’s disease : relevance for the behavioral and synaptic deficits induced by amyloid beta protein
    Medeiros R J Neurosci 27 : 5394 ~ 5404 [2007]
  • Complement activation by beta-amyloid in Alzheimer disease
    Rogers J Proc Natl Acad Sci USA 89 : 10016 ~ 10020 [1992]
  • Complement activation and beta-amyloid-mediated neurotoxicity in Alzheimer’s disease
    Rogers J Res Immunol 143 : 624 ~ 630 [1992]
  • Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis
    Kayed R Science 300 : 486 ~ 489 [2003]
  • Clusterin promotes amyloid plaque formation and is critical for neuritic toxicity in a mouse model of Alzheimer’s disease
    DeMattos RB Proc Natl Acad Sci U S A 99 : 10843 ~ 10848 [2002]
  • Clinical effects of Abeta immunization(AN1792)in patients with AD in an interrupted trial
    Gilman S Neurology 64 : 1553 ~ 1562 [2005]
  • Clearing the brain’s amyloid cobwebs
    Selkoe DJ Neuron 32 : 177 ~ 180 [2001]
  • Clearance of Alzheimer’s amyloidss(1-40)peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier
    Shibata M J Clin Invest 106 : 1489 ~ 1499 [2000]
  • Cholesterol-dependent gamma-secretase activity in buoyant cholesterol-rich membrane microdomains
    Wahrle S Neurobiol Dis 9 : 11 ~ 23 [2002]
  • Cerebrovascular effects of apolipoprotein E : implications for Alzheimer disease
    Zlokovic BV JAMA Neurol 70 : 440 ~ 444 [2013]
  • Cell signaling pathways and iron chelation in the neurorestorative activity of green tea polyphenols : special reference to epigallocatechin gallate(EGCG)
    Mandel SA J Alzheimers Dis 15 : 211 ~ 222 [2008]
  • CHF5074, a novel gamma-secretase modulator, attenuates brain beta-amyloid pathology and learning deficit in a mouse model of Alzheimer’s disease
    Imbimbo BP Br J Pharmacol 156 : 982 ~ 993 [2009]
  • Blocking TGF-beta-Smad2/3 innate immune signaling mitigates Alzheimer-like pathology
    Town T Nat Med 14 : 681 ~ 687 [2008]
  • Beta-amyloid immunotherapy prevents synaptic degeneration in a mouse model of Alzheimer’s disease
    Buttini M J Neurosci 25 : 9096 ~ 9101 [2005]
  • Begacestat(GSI-953): a novel, selective thiophene sulfonamide inhibitor of amyloid precursor protein gamma-secretase for the treatment of Alzheimer’s disease
    Martone RL J Pharmacol Exp Ther 331 : 598 ~ 608 [2009]
  • Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer’s disease
    Holtzman DM Proc Natl Acad Sci U S A 97 : 2892 ~ 2897 [2000]
  • Anti-amyloid-beta immunotherapy in Alzheimer’s disease : ACC-001 clinical trials are ongoing
    Ryan JM J Alzheimers Dis 17 : 243 ~ [2009]
  • An effector-reduced anti-beta-amyloid(Abeta)antibody with unique abeta binding properties promotes neuroprotection and glial engulfment of Abeta
    Adolfsson O J Neurosci 32 : 9677 ~ 9689 [2012]
  • Amyloidogenic processing of the Alzheimer beta-amyloid precursor protein depends on lipid rafts
    Ehehalt R J Cell Biol 160 : 113 ~ 123 [2003]
  • Amyloid-ß-directed immunotherapy for Alzheimer’s disease
    Lannfelt L Journal of Internal Medicine 275 : 284 ~ 295 [2014]
  • Amyloid-related imaging abnormalities in patients with Alzheimer’s disease treated with bapineuzumab : a retrospective analysis
    Sperling R Lancet Neurol 11 : 241 ~ 249 [2012]
  • Amyloid-beta protein dimers isolated directly from Alzheimer’s brains impair synaptic plasticity and memory
    Shankar GM Nat Med 14 : 837 ~ 842 [2008]
  • Amyloid-beta immunotherapy for Alzheimer’s disease : the end of the beginning
    Schenk D. Nat Rev Neurosci 3 : 824 ~ 828 [2002]
  • Amyloid imaging in aging and dementia : testing the amyloid hypothesis in vivo
    Rabinovici GD Behav Neurol 21 : 117 ~ 128 [2009]
  • Alzheimer’s disease: genotypes, phenotypes, and treatments
    Selkoe DJ Science 275 : 630 ~ 631 [1997]
  • Alzheimer’s disease in Down syndrome : neurobiology and risk
    Zigman WB Ment Retard Dev Disabil Res Rev 13 : 237 ~ 246 [2007]
  • Alzheimer’s disease : the amyloid cascade hypothesis
    Hardy JA Science 256 : 184 ~ 185 [1992]
  • Alzheimer’s disease : molecular understanding predicts amyloid-based therapeutics
    Selkoe DJ Annu Rev Pharmacol Toxicol 43 : 545 ~ 584 [2003]
  • Alzheimer’s Disease Cooperative Study Data A, Publication C. Phase 3 trials of solanezumab and bapineuzumab for Alzheimer’s disease
    Doody RS N Engl J Med 370 : 1460 ~ [2014]
  • Acyl-coenzyme A : cholesterol acyltransferase modulates the generation of the amyloid beta-peptide
    Puglielli L Nat Cell Biol 3 : 905 ~ 912 [2001]
  • APPSw transgenic mice develop age-related A beta deposits and neuropil abnormalities, but no neuronal loss in CA1
    Irizarry MC J Neuropathol Exp Neurol 56 : 965 ~ 973 [1997]
  • A phase 3 trial of semagacestat for treatment of Alzheimer’s disease
    Doody RS N Engl J Med 369 : 341 ~ 350 [2013]
  • A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease
    Salloway S Neurology 77 : 1253 ~ 1262 [2011]
  • A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease
    Salloway S Neurology 73 : 2061 ~ 2070 [2009]
  • A Phase II study targeting amyloidbeta with 3APS in mild-to-moderate Alzheimer disease
    Aisen PS Neurology 67 : 1757 ~ 1763 [2006]